Plasma Assay of Matrix Metalloproteinases (MMPs) and MMP‐Inhibitor Complexes in Cancer

Zucker, Stanley; Lysik, Rita M.; Zarrabi, Hosein M.; Moll, Ute M.; Tickle, Simon; Stetler-Stevenson, William G.; Baker, Terry; Docherty, Andrew

doi:10.1111/j.1749-6632.1994.tb24740.x

Cited by 36 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this way, 4 bands of gelatinolytic activity were detected. Other authors (Zucker et al, 1994;Vartio et al, 1989) obtained the same pattern of bands employing a more complex methodology, e.g., Sepharose chromatography followed by zymography (Zucker et al, 1994). When whole plasma or serum was employed, we could only detect slight MMP activity in comparison with euglobulins.…”

Section: Lung Cancer Patientsmentioning

confidence: 68%

See 1 more Smart Citation

Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients

Farías¹,

Ranuncolo²,

Cresta³

et al. 2000

Int. J. Cancer

View full text Add to dashboard Cite

Section: Lung Cancer Patientsmentioning

confidence: 68%

“…The method developed in our laboratory was highly specific and reproducible. Zucker et al (1994) demonstrated that the vast majority of plasma gelatinases circulate as latent enzymes. We do not know for certain why the acetic precipitation of plasma proteins is highly effective to reveal the activity of MMPs.…”

Section: Lung Cancer Patientsmentioning

confidence: 99%

Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients

Farías¹,

Ranuncolo²,

Cresta³

et al. 2000

Int. J. Cancer

View full text Add to dashboard Cite

“…TIMPs bind to the active site of MMP in a 1:1 stoichiometrie, blocking their access to collagen substrate [15,98]. Furthermore they can bind latent MMPs at the aminoterminus thereby preventing their activation [99]. Some differences in the inhibitory properties of the different TIMPs have been reported.…”

Section: Inhibition Of Mmpsmentioning

confidence: 98%

Myocardial proteases and matrix remodeling in inflammatory heart disease

Rutschow

Schultheiss

et al. 2006

Cardiovascular Research

View full text Add to dashboard Cite

Recently, it has been demonstrated that myocardial inflammation plays a pivotal role in the development and progression of congestive heart failure. The myocardial inflammatory reaction not only affects myocardial hypertrophy and apoptosis, but it has a major influence on the regulation of extracellular matrix turnover. The balance between collagen synthesis and degradation is of crucial relevance in maintaining the structural integrity of the heart. Therefore, the overwhelming inflammatory response, as seen in acute myocarditis or inflammatory cardiomyopathy, could lead to a breakdown of this tightly regulated system. This is an additional key factor in the development and progression of heart failure. This review summarizes the importance of myocardial inflammation in respect to extracellular matrix remodeling and its possible patho-physiological role in the development and progression of left ventricular dysfunction in inflammatory heart disease.

show abstract

“…TIMPs interact with the zinc binding site of the catalytic domain of active MMPs and prevent substrate access. They can also bind the latent MMPs at the amino terminus to prevent autoactivation (14) and have some degree of specificity for MMP inhibition. TIMP-1 potently inhibits the activity of most MMPs, with the exception of MMP-2 and MT1-MMP.…”

Section: Les Métalloprotéinases Matricielles Et L'infarctus Du Myocardementioning

confidence: 99%

Matrix metalloproteinases and myocardial infarction

Phatharajaree

Phrommintikul

Chattipakorn

2007

Canadian Journal of Cardiology

View full text Add to dashboard Cite

A cute myocardial infarction (AMI) is one of the most important health problems in many nations around the world. It may be found in many age groups, but is predominant among elderly people (1). The incidence of AMI has been increasing, possibly due to the changes in lifestyle and dietary intake that lead to an increase in coronary risk factors for cardiovascular disease.AMI has devastating consequences in the early phase, such as cardiac rupture, and in the chronic phase, such as chronic heart failure, for which the risk is mainly determined by infarct size (2). Larger infarct size induces gross morphological, histological and molecular changes of the infarcted and noninfarcted regions. These changes are known as the cardiac remodelling process. The degree of cardiac remodelling is closely related to the incidence of cardiac arrhythmias, heart failure and mortality (3). Cardiac remodelling involves changes in cardiac myocytes and in the extracellular matrix (ECM). The ECM contains a wide array of structural proteins, such as fibrillar collagen, proteoglycans and glycosaminoglycans, and serves as a reservoir for biologically active molecules. Because myocardial collagens maintain the structural integrity of adjoining myocytes and provide the means by which myocyte shortening is translated into cardiac pump function, changes in the ECM result in a loss of normal structural and functional myocardium.Matrix metalloproteinase (MMP) is a proteolytic enzyme that has been identified in the myocardium, and is likely to contribute to ECM changes and myocardial remodelling. In the past few decades, growing evidence from basic and clinical studies have demonstrated the important role of MMPs in the progression of left ventricular dimension, remodelling and mortality following AMI. In the present article, MMP expression after AMI and its role as a possible prognostic marker are reviewed. Currently available data regarding the role of MMP inhibitors as a possible novel therapeutic intervention are also discussed. Acute myocardial infarction (AMI) is currently one of the most important health problems in many countries around the world. Following AMI, many cytokines and proteolytic enzymes are released. Among these, matrix metalloproteinases (MMPs) are important proteolytic enzymes that lead to degradation of the extracellular matrix and to changes in cardiomyocytes in both infarcted and noninfarcted myocardium. This process is known as cardiac remodelling. It has been demonstrated that more than one type of MMP is present in the circulation after cardiomyocyte injury. A number of studies have demonstrated the correlations between these MMP levels and the severity of a coronary lesion, the progression of left ventricular dimension and the survival rate following AMI in both animal and human studies. MMPs have also been proposed as a possible novel prognostic indicator for myocardial infarction patients. Although the use of MMP inhibitors to improve cardiac outcome in AMI patients has been investigated, discrepancies in the re...

show abstract

Plasma Assay of Matrix Metalloproteinases (MMPs) and MMP‐Inhibitor Complexes in Cancer

Cited by 36 publications

References 20 publications

Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients

Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients

Myocardial proteases and matrix remodeling in inflammatory heart disease

Matrix metalloproteinases and myocardial infarction

Contact Info

Product

Resources

About